Shares of Novartis NVS decreased 3.8% in pre-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share increased 1.52% over the past year to $1.34, which missed the estimate of $1.36.
Revenue of $12,770,000,000 rose by 2.96% year over year, which missed the estimate of $12,870,000,000.
Guidance
Novartis hasn't issued any earnings guidance for the time being.
Novartis hasn't issued any revenue guidance for the time being.
Details Of The Call
Date: Jan 26, 2021
Time: 08:00 AM
ET Webcast URL: https://edge.media-server.com/mmc/p/g655yyy5
Price Action
52-week high: $99.84
Company's 52-week low was at $69.18
Price action over last quarter: Up 20.93%
Company Profile
Novartis AG develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.